PUBERTY BLOCKERS RETURN: The Shocking NHS Loophole That Bypasses The Ban

I explore the controversial NHS Pathways clinical trial involving puberty blockers for children, examining ethical, biological, and legal concerns. I I highlights the risks and calls for greater child protection and evidence-based care.Chapters00:00 Introduction to the NHS Pathways Trial and Legal Challenge02:23 The Role of the Hilary Cass Review05:15 Why This Trial Is Dangerous for Children08:10 Brain Development and Cognitive Risks09:20 Ethical Violations in the Trial11:01 Contradictions and Ethical Failures12:19 Why Gender Dysphoria Treatments Are Exempt from Safeguards13:17 The Voice of Detransitioners and Future Risks14:16 Call to Action for Child Safety and Evidence-Based Care14:47 Closing Remarks and Community EngagementResources:Hilary Cass Review 2024 - https://www.gov.uk/government/publications/hilary-cass-review-2024NHS Pathways Clinical Trial Details - https://www.nhs.uk/conditions/gender-dysphoria/Declaration of Helsinki - https://www.wma.net/policies-post/wma-declaration-of-helsinki/💬 JOIN THE CONVERSATION:Can an 11-year-old give informed consent to treatments that impact future fertility? Should public health trials proceed when long-term risks are established? Sound off in the comments below!#PubertyBlockers #ChildSafeguarding #CassReview #HighCourt #UKNews #MedicalEthics #CommonSense